Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Capstone Therapeutics Corp (OTC: CAPS).

Full DD Report for CAPS

You must become a subscriber to view this report.


Recent News from (OTC: CAPS)

LipimetiX Development Announces Sub-License of Apo E Mimetic Peptide Platform to Anji Pharma, China
NATICK, Mass., May 07, 2018 (GLOBE NEWSWIRE) -- LipimetiX Development, Inc. (“LipimetiX” or “the Company”) announced today that Anji Pharmaceuticals, Inc. (“Anji Pharma”) has entered a licensing agreement for the LipimetiX platform of peptides (...
Source: GlobeNewswire
Date: May, 07 2018 09:00
Evolve Announces March 2018 Distributions for Evolve ETFs
Evolve Announces March 2018 Distributions for Evolve ETFs
Source: OTC Markets
Date: March, 15 2018 00:00
Capstone Therapeutics Announces Transaction for Sale of Shares of Its Common Stock and Secured Loan
TEMPE, Ariz., July 17, 2017 (GLOBE NEWSWIRE) -- Capstone Therapeutics Corp. (OTCQB:CAPS) (“the Company”) announced today that on July 14, 2017, BP Peptides, LLC (“Brookstone”) purchased 13,500,000 newly issued shares of Capstone Common Stock, for $1,012,500 (...
Source: GlobeNewswire
Date: July, 17 2017 08:01
Capstone Therapeutics Announces Profound, Rapid LDL Cholesterol Reduction in AEM-28-14 Primate Study
TEMPE, Ariz., Dec. 19, 2016 (GLOBE NEWSWIRE) -- Capstone Therapeutics Corp. (OTCQB:CAPS) (“the Company”) and LipimetiX Development, Inc., the Company’s drug development joint venture (“ JV ”) announced today that the JV’s lead commercial drug ca...
Source: GlobeNewswire
Date: December, 20 2016 01:10
Capstone Therapeutics Announces That Its Joint Venture, LipimetiX Development, Inc., Has Closed a Series B-1 Preferred Stock Offering
TEMPE, Ariz., Aug. 25, 2016 (GLOBE NEWSWIRE) -- Capstone Therapeutics Corp. (OTCQB:CAPS) (“the Company”) and LipimetiX Development, Inc., the Company’s drug development joint venture (“ JV ”) announced today that the JV’s Series B-1 preferred st...
Source: GlobeNewswire
Date: August, 25 2016 09:01
Capstone Therapeutics Announces Existing Shareholder Decision Not to Extend Exclusive due Diligence Period
TEMPE, Ariz., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Capstone Therapeutics Corp. (OTCQB:CAPS) (“the Company”) and LipimetiX Development, Inc., the Company’s 60% owned joint venture (“ JV ”) announced today that the Lenders, as defined in the Company’...
Source: GlobeNewswire
Date: February, 03 2016 15:29
Capstone Therapeutics Announces Loan From Existing Shareholder for Exclusive Due Diligence Period
TEMPE, Ariz., Dec. 15, 2015 (GLOBE NEWSWIRE) -- Capstone Therapeutics Corp. (OTCQB:CAPS) (“the Company”) and LipimetiX Development, Inc., the Company’s 60% owned joint venture (“ JV ”) announced today that the Biotechnology Value Fund, L.P. and other a...
Source: GlobeNewswire
Date: December, 15 2015 16:15
Top 2 Trade Alert Ideas October 14: Portola Milestone, Edge Granted ODD, Beaten Down Stocks
This week, Zafgen (ZFGN) has lost almost two thirds of its market cap after the company halted its beloranib clinical trial. As per the latest update, a partial clinical hold has been placed on beloranib clinical trials. Such setbacks are quite common in the biotech world. But is it worth inve...
Source: SeekingAlpha
Date: October, 16 2015 16:12
Capstone Therapeutics Announces Allowance of U.S. Patent for Treatment of Diabetes With Apo E Mimetic Peptides
TEMPE, Ariz., Oct. 14, 2015 (GLOBE NEWSWIRE) -- Capstone Therapeutics, Inc. (OTCQB:CAPS) ("the Company") and its (60% owned) joint venture affiliate, LipimetiX Development, Inc. ("JV"), announced today the allowance of U.S. Patent application number 12/675,089 for the use of apolipopr...
Source: GlobeNewswire
Date: October, 14 2015 09:01
Capstone Therapeutics Announces Second Quarter 2015 Financial Results and Operating Update Conference Call
Capstone Therapeutics Announces Second Quarter 2015 Financial Results and Operating Update Conference Call
Source: OTC Markets
Date: August, 10 2015 00:00

 


About Capstone Therapeutics Corp (OTC: CAPS)

Logo for Capstone Therapeutics Corp (OTC: CAPS)

Capstone Therapeutics Corp. is a biotechnology company committed to developing a pipeline of novel therapeutic peptides aimed at helping patients with under served medical conditions.

 

 

 

Current Management

  • John M Holliman / CEO
  • Les Taeger / CFO
  • Barbara Dunford / Executive Assistant
  • John M Holliman / Chairman
  • Frederic J Feldman /
  • Elwood D Howse /
  • Matthew E. Lipman / Audit Committee Member
    • Mr. Lipman has served as a director of Mechanical Technology, Incorporated MKTY since October , . Since , Mr. Lipman has served as Managing Director of Brookstone Partners, a lower middle market private equity firm based in New York and an affiliate of BP Peptides, LLC. Mr. Lipman s responsibilities at Brookstone Partners include identifying and evaluating investment opportunities, performing transaction due diligence, managing the capital structure of portfolio companies and working with management teams to implement operational and growth strategies. In addition, Mr. Lipman is responsible for executing addon acquisitions and other portfolio companyrelated strategic projects. From July through June , Mr. Lipman was an analyst in the mergers and acquisitions group at UBS Financial Services Inc. responsible for formulating and executing on complex merger, acquisition and financing strategies for Fortune companies in the industrial, consumer products and healthcare sectors. Mr. Lipman currently serves on the Board of Directors of Instone, LLC and Denison Pharmaceuticals, LLC. Mr. Lipman has a B.S. in Business Administration from Babson College. Mr. Lipman brings over years of experience working with companies to establish growth strategies and execute acquisitions, is proficient in reading and understanding financial statements, generally accepted accounting principles and internal controls as a direct result of his investment experience evaluating companies for potential investments, the management of financial reporting and capital structure for three portfolio companies, as well as relevant experience in board service, which the Board believes qualifies him to serve as a director. In addition, his experience working with the Chief Financial Officers of portfolio companies to manage and analyze businesses and manage the capital structure of operating companies makes him well qualified for his service on the Audit Committee.
  • Michael M. Toporek / Compensation Committee Member
    • Mr. Toporek has served as a director of Mechanical Technology, Incorporated MKTY since October , . Since , Mr. Toporek has served as the Managing General Partner of Brookstone Partners, a lower middle market private equity firm based in New York and an affiliate of BP Peptides, LLC. Prior to founding Brookstone Partners in , Mr. Toporek was both an active principal investor and an investment banker. Mr. Toporek began his career in Chemical Bank s Investment Banking Group, later joined Dillon, Read and Co., which became UBS Warburg Securities Ltd. during his tenure, and SG Cowen and Company. Mr. Toporek currently serves on the Board of Trustees of Harlem Academy. Mr. Toporek has a B.A. in Economics and an M.B.A from the University of Chicago. Mr. Toporek brings strategic and financial expertise to the Board as a result of his experience with Brookstone Partners, which the Board believes qualifies him to serve as a director.

Current Share Structure

  • Market Cap: $2,447,343 - 03/16/2018
  • Authorized: 150,000,000 - 03/15/2018
  • Issue and Outstanding: 54,385,411 - 03/15/2018

 


Recent Filings from (OTC: CAPS)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 07 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: February, 28 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 01 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: February, 01 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: January, 23 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 13 2017
Amendment to a previously filed 10-K
Filing Type: 10-K/AFiling Source: edgar
Filing Date: October, 30 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 14 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 14 2017

 

 


Daily Technical Chart for (OTC: CAPS)

Daily Technical Chart for (OTC: CAPS)


Stay tuned for daily updates and more on (OTC: CAPS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: CAPS)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

Monsta Trader
@MonstaTrader

 

 


Disclaimer: Monsta Trader publishes reports providing information on selected companies. Monsta Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. Monsta Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CAPS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Monsta Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. Monsta Trader does not own any shares of CAPS and does not buy, sell, or trade any shares of CAPS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by Monsta Trader. All rights reserved. Our Full Disclaimer: http://monstatrader.com/disclaimer/